Skip to main content

ASCO 2017 - Chronic Lymphocytic Leukemia

ASCO 2017 - Chronic Lymphocytic Leukemia

Phase 1 Dose Escalation of Ibrutinib and Buparlisib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Mantle-Cell Lymphoma, and Follicular Lymphoma

ASCO 2017 - Chronic Lymphocytic Leukemia

KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with CLL Intolerant to Prior Bruton’s Tyrosine Kinase or PI3Kδ Inhibitor Therapy

ASCO 2017 - Chronic Lymphocytic Leukemia

iFCG for Previously Untreated Patients with CLL with Mutated IGHV and Non-Del(17p)

ASCO 2017 - Chronic Lymphocytic Leukemia

Results of a Phase 2 Multicenter Study of Obinutuzumab plus Bendamustine in Patients with Previously Untreated CLL

ASCO 2017 - Chronic Lymphocytic Leukemia

CD19 CAR T-Cells Combined with Ibrutinib to Induce Complete Remission in CLL

ASCO 2017 - Chronic Lymphocytic Leukemia

Combination Ibrutinib and Venetoclax for the Treatment of MCL: Primary End Point Assessment of the Phase 2 AIM Study

ASCO 2017 - Chronic Lymphocytic Leukemia

A Phase 1a/1b Study of a Novel BTK Inhibitor and Combination Products with Everolimus and Pomalidomide in Patients with CLL or Other B-Cell Lymphomas

ASCO 2017 - Chronic Lymphocytic Leukemia

Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Patients with TN FL (PERSPECTIVE)

ASCO 2017 - Chronic Lymphocytic Leukemia

Tolerability and Activity of the Chemotherapy-Free Triplet TGR-1202, Ublituximab, and Ibrutinib in Patients with Advanced CLL and NHL

ASCO 2017 - Chronic Lymphocytic Leukemia

Randomized, Double-Blind Phase 3 Study of Ibrutinib versus Placebo in Combination with Corticosteroids in Patients with New-Onset cGVHD

Page 1 of 2
Results 1 - 10 of 16